Ian W. Flinn, MD, PhD / Caron Jacobson, MD / Preetesh Jain, MBBS, MD, DM, PhD -Rewriting Patient Care in Mantle Cell Lymphoma: How Innovative Therapy Is Poised to Challenge Conventional Treatment

Go online to PeerView.com/MBT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The recent emergence and regulatory approval of multiple novel agent classes, such as Bruton’s tyrosine kinase (BTK) inhibitors and immunomodulatory drugs (IMiDs), in the management of mantle cell lymphoma (MCL) has offered clinicians and patients a greater variety of effective therapeutic options in this challenging clinical setting. At the same time, researchers continue to assess the potential of BCL-2 targeting agents and BTK inhibitor combinations, while new science has led to the regulatory approval of chimeric antigen receptor (CAR)-T cell therapy in relapsed disease. In this “Clinical Consults” activity, experts will offer guidance on key findings that have decisively turned the field away from chemotherapy-centric care. Upon completion of this activity, participants should be better able to: Summarize current recommendations for managing newly diagnosed and relapsed/refractory MCL based on factors such as treatment history, disease characteristics, or need for aggressive therapy, Discuss evidence surrounding novel treatment regimens that include BTK inhibitor, BCL-2 inhibitor, immunomodulatory, or adoptive cell therapy components across the MCL disease spectrum, Recommend therapy with novel components for the management of patients with MCL after consideration of baseline prognostic factors and/or treatment history, Manage the unique spectrum of adverse events associated with novel therapeutics in patients with MCL.